Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. Show more
Location: Suite 1, 3rd Floor, London, SW1Y 4LB, United Kingdom | Website: www.axovant.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$0.47
Open
$0.45
Volume
40,403
Day Range
$0.45 - $0.48
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
25.26%
Institutional Own.
0.20%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXO-AAV-GM1 (GLB1) Details GM1 gangliosidosis, Lysosomal storage disorder | Failed Discontinued | |
AXO-AAV-GM2 Details Tay-Sachs/Sandhoff disease, GM2 gangliosidosis, Lysosomal storage disorder | Failed Discontinued | |
AXO-Lenti-PD (OXB-102) Details Parkinson's disease | Failed Discontinued |